A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Lemborexant (Primary) ; Suvorexant; Zolpidem
- Indications Insomnia
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 30 Jul 2018 Status changed from recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 1 Jan 2018 to 13 Jul 2018.
- 30 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 13 Jul 2018.